Effect of addition of Ondansetron or Magnesium to Lidocaine on duration of analgesia of intravenous regional anesthesia in elective upper extremities surgery: comparative study.

BackgroundThis study aimed at evaluating and comparing the effect of ondansetron and magnesium added to lidocaine on intravenous regional anesthesia (IVRA) in the surgery of upper extremity.Settings and design The current randomized, clinical trial was conducted on 45 patients considered as candidates for upper extremities surgery in Qazvin, Iran. The patients were randomly assigned into three groups. Group C only received 3 mg/kg lidocaine, group O lidocaine + 4 mg/kg ondansetron, and group M lidocaine + 7.5 mL magnesium sulfate 20%. Then, the sensory and motor blocks, tourniquet pain, the amount of administered extra fentanyl, pain intensity, and other parameters involved in analgesia were analyzed in the groups using the statistical tests.ResultsThe time for onset of sensory and motor blocks in group M was significantly shorter than the groups C and O (P <0.05). In terms of the recovery time of sensory block, the time of group O was significantly longer than those of groups M and C (P <0.05). The amount of administered extra fentanyl and tourniquet pain after block in groups O and M were significantly lower than those of group C (P< 0.05). No significant difference was observed in postoperative pain and other features among the groups (P >0.05).ConclusionMagnesium had more rapid effectiveness and ondansetron had prolonged postoperative analgesia. Although the induced analgesia relatively improved the intensity of pain, it failed to maintain its supremacy in postoperative pain. To obtain more conclusive results, further studies are required.BackgroundThis study aimed at evaluating and comparing the effect of ondansetron and magnesium added to lidocaine on intravenous regional anesthesia (IVRA) in the surgery of upper extremity.Settings and design The current randomized, clinical trial was conducted on 45 patients considered as candidates for upper extremities surgery in Qazvin, Iran. The patients were randomly assigned into three groups. Group C only received 3 mg/kg lidocaine, group O lidocaine + 4 mg/kg ondansetron, and group M lidocaine + 7.5 mL magnesium sulfate 20%. Then, the sensory and motor blocks, tourniquet pain, the amount of administered extra fentanyl, pain intensity, and other parameters involved in analgesia were analyzed in the groups using the statistical tests.ResultsThe time for onset of sensory and motor blocks in group M was significantly shorter than the groups C and O (P <0.05). In terms of the recovery time of sensory block, the time of group O was significantly longer than those of groups M and C (P <0.05). The amount of administered extra fentanyl and tourniquet pain after block in groups O and M were significantly lower than those of group C (P< 0.05). No significant difference was observed in postoperative pain and other features among the groups (P >0.05).ConclusionMagnesium had more rapid effectiveness and ondansetron had prolonged postoperative analgesia. Although the induced analgesia relatively improved the intensity of pain, it failed to maintain its supremacy in postoperative pain. To obtain more conclusive results, further studies are required

Effect of addition of ondansetron or magnesium to lidocaine on duration of analgesia of intravenous regional anesthesia in elective upper extremities surgery: Comparative study

Background: This study aimed at evaluating and comparing the effect of ondansetron and magnesium added to lidocaine on intravenous regional anesthesia (IVRA) in the surgery of upper extremity. Methods and Materials: The current randomized, clinical trial was conducted on 45 patients considered as candidates for upper extremities surgery in Qazvin, Iran. The patients were randomly assigned into three groups. Group C only received 3 mg/kg lidocaine, group O lidocaine +4 mg/kg ondansetron, and group M lidocaine +7.5 mL magnesium sulfate 20%. Then, the sensory and motor blocks, tourniquet pain, the amount of administered extra fentanyl, pain intensity, and other parameters involved in analgesia were analyzed in the groups using the statistical tests. Results: The time for onset of sensory and motor blocks in the M group was significantly shorter than the groups C and O (p<0.05). In terms of the recovery time of the sensory block, the time of group O was significantly longer than those of groups M and C (p<0.05). The amount of administered extra fentanyl and tourniquet pain after block in groups O and M were significantly lower than of group C (p<0.05). No significant difference was observed in postoperative pain and other features among the groups (p>0.05). Conclusion: Magnesium had more rapid effectiveness and ondansetron had prolonged postoperative analgesia. Although the induced analgesia relatively improved the intensity of pain, it failed to maintain its supremacy in postoperative pain. To obtain more conclusive results, further studies are required. Keywords: Bier Block, Ondansetron, Magnesium, Lidocain

Exploring the interplay between Fusobacterium nucleatum with the expression of microRNA, and inflammatory mediators in colorectal cancer

BackgroundFusobacterium nucleatum has been recognized as an important key bacterium in the cause and spread of colorectal carcinogenesis. Nevertheless, the clinical relevance of F. nucleatum in colorectal cancer (CRC) and its effect on immune factors and the tumor microenvironment have not been fully elucidated.Materials and methodsThe frequency of F. nucleatum was measured in 100 paired tumor and normal tissue specimens by TaqMan quantification Real-Time Polymerase Chain Reaction (qPCR). The mRNA expression levels of cytokines (IL-6, IL-10, IL-12β, IL-17, TNF-α, TLR-2, and TLR-4), and miRNAs (miR-21, miR-31) were examined. Eventually, any potential correlations between the molecular and clinicopathological features of the neoplastic samples and the abundance of F. nucleatum were analyzed.ResultsThe relative frequency of F. nucleatum was significantly increased in cancerous tissue compared to adjacent non-tumor tissues. Furthermore, the high level of F. nucleatum was significantly associated with histological grade III and IV CRC tissues (P = 0.027 and P = 0.022, respectively) and perineural invasion-positive patients (P = 0.037). In addition, the expression levels of IL-6, IL-17, TNF-α,IL-12β, TLR-2, and TLR-4 as well as miR-21 and miR-31 showed a significant increase in the cancer group. A notable correlation was also observed between the high status of F. nucleatum and the expression of IL-6, TNF-α and miR-21.ConclusionOur results emphasize the importance of F. nucleatum and changes in the expression of genes involved in CRC. Studying the microbial profile and gene expression changes in CRC patients may be a promising approach to improve screening methods and provide therapeutic strategies

Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking

SARS-CoV-2 (COVID-19) is the causative organism for a pandemic disease with a high rate of infectivity and mortality. In this study, we aimed to assess the affinity between several available small molecule and proteins, including Abl kinase inhibitors, Janus kinase inhibitor, dipeptidyl peptidase 4 inhibitors, RNA-dependent RNA polymerase inhibitors, and Papain-like protease inhibitors, using binding simulation, to test whether they may be effective in inhibiting COVID-19 infection through several mechanisms. The efficiency of inhibitors was evaluated based on docking scores using AutoDock Vina software. Strong ligand–protein interactions were predicted among some of these drugs, that included: Imatinib, Remdesivir, and Telaprevir, and this may render these compounds promising candidates. Some candidate drugs might be efficient in disease control as potential inhibitors or lead compounds against the SARS-CoV-2. It is also worth highlighting the powerful immunomodulatory role of other drugs, such as Abivertinib that inhibits pro-inflammatory cytokine production associated with cytokine release syndrome (CRS) and the progression of COVID-19 infection. The potential role of other Abl kinase inhibitors, including Imatinib in reducing SARS-CoV and MERS-CoV viral titers, immune regulatory function and the development of acute respiratory distress syndrome (ARDS), indicate that this drug may be useful for COVID-19, as the SARS-CoV-2 genome is similar to SARS-CoV

Impact of Intravenous Trehalose Administration in Patients with Niemann–Pick Disease Types A and B

Background and aims: Niemann-Pick disease (NPD) types A (NPA) and B (NPB) are caused by deficiency of the acid sphingomyelinase enzyme, which is encoded by the SMPD1 gene, resulting in progressive pathogenic accumulation of lipids in tissues. Trehalose has been suggested as an autophagy inducer with therapeutic neuroprotective effects. We performed a single-arm, open-label pilot study to assess the potential efficacy of trehalose treatment in patients with NPA and NPB patients. ------ Methods: Five patients with NPD type A and B were enrolled in an open-label, single-arm clinical trial. Trehalose was administrated intravenously (IV) (15 g/week) for three months. The efficacy of trehalose in the management of clinical symptoms was evaluated in patients by assessing the quality of life, serum biomarkers, and high-resolution computed tomography (HRCT) of the lungs at the baseline and end of the interventional trial (day 0 and week 12). ----- Results: The mean of TNO-AZL Preschool children Quality of Life (TAPQOL) scores increased in all patients after intervention at W12 compared to the baseline W0, although the difference was not statistically significant. The serum levels of lyso-SM-509 and lyso-SM were decreased in three and four patients out of five, respectively, compared with baseline. Elevated ALT and AST levels were decreased in all patients after 12 weeks of treatment; however, changes were not statistically significant. Pro-oxidant antioxidant balance (PAB) was also decreased and glutathione peroxidase (GPX) activity was increased in serum of patients at the end of the study. Imaging studies of spleen and lung HRCT showed improvement of symptoms in two patients. ----- Conclusions: Positive trends in health-related quality of life (HRQoL), serum biomarkers, and organomegaly were observed after 3 months of treatment with trehalose in patients with NPA and NPB. Although not statistically significant, due to the small number of patients enrolled, these results are encouraging and should be further explored

Effects of Trehalose Administration in Patients with Mucopolysaccharidosis Type III.

Mucopolysaccharidosis type III (MPS III) is a rare autosomal recessive lysosomal storage disease (LSD) caused by a deficiency of lysosomal enzymes required for the catabolism of glycosaminoglycans (GAGs), mainly in the central nervous system. Trehalose has been proposed as a potential therapeutic agent to attenuate neuropathology in MPS III. We conducted a single-arm, open-label study to evaluate the efficacy of trehalose treatment in patients with MPS IIIA and MPS IIIB. Five patients with MPS III were enrolled. Trehalose was administrated intravenously (15 g/week) for 12 weeks. Health-related quality of life and cognitive function, serum biomarkers, liver, spleen, and lung imaging were assessed to evaluate trehalose efficacy at baseline and trial end (week 12). TNO-AZL Preschool children Quality of Life (TAPQOL) scores increased in all patients, and the mean scores for quality of life were increased after the intervention. Serum GAG levels were reduced in all treated patients (however, the differences were not statistically significant). Alanine aminotransferase (ALT) levels were reduced in all patients post-treatment (p=0.0039). The mean levels of aspartate transaminase (AST) were also decreased after 12 weeks of treatment with Trehalose. Decreased serum pro-oxidant-antioxidant balance and increased GPX activity were observed at the end of the study. Decreases in mean splenic length were observed, whereas the liver volume did not change. Improvements in health-related quality of life and serum biomarkers (GAGs, liver aminotransferase levels, antioxidant status), as well as liver and spleen size, were found following 3 months of trehalose administration in patients with MPS IIIA and MPS IIIB

The effects of oral trehalose on glycaemia, inflammation, and quality of life in patients with type 2 diabetes: a pilot randomized controlled trial

Introduction: Trehalose is a naturally occurring disaccharide of 2 glucose molecules, which has been suggested as a potential therapeutic agent to reduce blood glucose and ameliorate diabetes-related complications in type 2 diabetes (T2D). This study aimed to determine the efficacy of medium-term trehalose treatment in patients with T2D. Material and methods: A double-blind, randomized, placebo-controlled trial in 40 patients with T2D was undertaken; 20 ingested trehalose 3.3 g/day and 20 placebo (sucrose), for 3 months. Parameters of glycaemic indices, high-sensitivity C-reactive protein (CRP), mood status, and quality of life were measured. Results: CRP was significantly lower with trehalose treatment (-0.62 ±0.3 mg/l, p = 0.02); however, no differences in glycaemic indices of fasting blood glucose (FBG) (-7.1 ±10.7 mg/dl, p = 0.15), glycated hemoglobin (HbA1c) (-0.1 ±0.4%, p = 0.73), insulin (0.73 ±0.8 μU/ml, p = 0.39), or insulin resistance (HOMA-IR) (0.19 ±0.33, p = 0.56) were seen between groups after 12 weeks. Depression and stress scores were lower with trehalose compared to the placebo group (p = 0.02 and p = 0.05, respectively), whilst the quality-of-life score was higher with trehalose compared to placebo (p = 0.03) at the end of study. Between-group differences in these indices did not reach statistical significance (-2.36 ±1.20, -2.21 ±1.39 and 3.00 ±1.76 for depression, stress, and quality-of-life score, respectively) (p > 0.05). The pro-oxidant antioxidant balance (PAB) did not differ between groups (-4.6 ±12.8, p = 0.72). Conclusions: 12 weeks of treatment with 3.3 g/day of oral trehalose significantly improves CRP as a marker of inflammation, with potential favourable effects on quality of life, depression, and stress levels, but overall glycaemic control and pro-oxidant-antioxidant balance were unaltered during this time frame.</p